摘要
目的探讨人附睾蛋白4、糖类抗原125、D-二聚体的测定在卵巢癌诊断中的临床价值。方法选择2016年6月至2019年6月期间于锦州市中心医院就诊的经病理活检确诊为卵巢癌的患者90例(卵巢癌组),另外选择同期于锦州市中心医院接受诊疗的112例卵巢良性肿瘤患者(良性组),再选择同期于我院接受体检的健康女性125例(对照组)。抽取3组纳入对象空腹状态下肘静脉血,HE4、CA125采用化学发光微粒子免疫反应法予以测定,D-D采用免疫比浊法予以测定。比较3组纳入对象血清CA125、HE4及D-D水平;比较早期卵巢癌组与晚期卵巢癌组血清CA125、HE4及D-D水平;比较CA125、HE4及D-D单独检测与联合检测相关指标。结果 (1)对照组与良性组血清CA125、HE4及D-D水平差异均无统计学意义(P均>0.05),卵巢癌组血清上述指标水平均显著高于对照组及良性组(P=0.000);(2)晚期(Ⅲ-Ⅳ期)患者血清CA125、HE4及D-D水平水平均分别显著高于早期(Ⅰ-Ⅱ期)(P均<0.05);(3)CA125、HE4及D-D联合检测灵敏度及阳性预测值均显著高于3项指标单独检测(P均<0.05),联合检测特异度显著高于CA125及D-D(P均<0.05),3项联合检测与单项检测阴性预测值差异均无统计学意义(P均>0.05),3项联合检测Youden指数均分别显著高于单项检测(P均<0.05)。结论 CA125、HE4及D-D可作为临床诊断卵巢癌的重要指标,3者联合检测可提高卵巢癌检出结果,降低误诊或漏诊率,从而为临床治疗提供有效的依据。
Objective To investigate the clinical value of human epididymal protein 4,carbohydrate antigen 125 and D-dimer in the diagnosis of ovarian cancer.Methods 90 patients with ovarian cancer diagnosed by pathological biopsy from June 2017 to June 2020 were selected in our hospital(ovarian cancer group),112 patients with benign ovarian cancer who received diagnosis and treatment in our hospital during the same period(benign group),and 125 healthy women who received physical examination in our hospital during the same period(control group).Venous blood of the elbow under fasting state was extracted from the three groups.HE4 and CA125 were determined by chemiluminescent microparticle immunoreaction method,and D-D was determined by immunoturbidimetry.Serum LEVELS of CA125,HE4 and D-D were compared among the three groups.Serum LEVELS of CA125,HE4 and D-D were compared between the early ovarian cancer group and the advanced ovarian cancer group.The related indexes of CA125,HE4 and DD were compared.Results (1)there were no statistically significant differences in serum levels of CA125,HE4 and dd between the control group and the benign group(all P>0.05),and the serum levels of these indicators in the ovarian cancer group were significantly higher than those in the control group and the benign group(P=0.000).(2)The serum levels of CA125,HE4 and D-D in patients with advanced stage(STAGE Ⅲ-Ⅳ)were significantly higher than those in patients with early stage(StageⅠ-Ⅱ)(P<0.05).(3)the CA125,HE4 and D-D joint detection sensitivity and positive predictive value were significantly higher than 3 indicators detection alone(P<0.05),significantly higher than that of CA125 and joint detection of specific degrees D-D(P<0.05),3 joint detection and single negative predictive value differences had no statistical significance(P>0.05),3 joint detection Youden index were significantly higher than that of single test(P<0.05).Conclusion CA125,HE4 and D-D can be used as important indicators for clinical diagnosis of ovarian cancer.Combined detection of the three can improve the detection results of ovarian cancer and reduce the rate of misdiagnosis or missed diagnosis,thus providing an effective basis for clinical treatment.
作者
吕岩
王瑚
LV Yan;WANG Hu(Departmen of Oostetrics and Gymecology of Jinzhou Central Hospital,Jinzhou 121000,China)
出处
《中国实验诊断学》
2021年第1期54-56,共3页
Chinese Journal of Laboratory Diagnosis
关键词
卵巢癌
人附睾蛋白4
糖类抗原125
D-二聚体
诊断价值
Ovarian cancer
Human epididymal protein 4
Carbohydrate antigen 125
D-dimer
Diagnostic value
